Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors

Pharmacotherapy

Volumn 18, Issue 3, 1998, Pages 588-599

  White, C Michael ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENAZEPRIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; FOSINOPRIL; LISINOPRIL; MOEXIPRIL; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOSE LIVER FUNCTION RELATION; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; FEMALE; FOOD DRUG INTERACTION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; LIPOPHILICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STRUCTURE ACTIVITY RELATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS; RENIN-ANGIOTENSIN SYSTEM;

EID: 0031960225     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Kastrup EK, Hebel SK, Threlkeld DS, et al, eds. Facts and comparisons. St. Louis: Facts and Comparisons, 1996:164h-5p.
2. Foote EF, Haltenson CE. New therapeutic agents in the management of hypertension: angiotensin II-receptor antagonists and renin inhibitors. Ann Pharmacother 1993;27:1495-1503.
3. Schaefer KL, Porter JA. Angiotensin II receptor antagonists: the prototype losartan. Ann Pharmacother 1996;30:625-36.
4. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995;346:1403-7.
5. Munger MA, Furniss SM. Angiotensin II receptor blockers: novel therapy for heart failure? Pharmacotherapy 1996;16(2 pt 2):59S-68.
6. Bauer JH, Reams GP. The angiotensin II type-1 receptor antagonists: a new class of antihypertensive drugs. Arch Intern Med 1995;155:1361-8
7. Goodfriend TL, Elliot ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-53.
8. Tomiyama H, Kushiro T, Abeta H, et al. Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension 1994;23:450-5.
9. Israili Z, Hall D. Cough and angioneurotic edema associated with angiotensin converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42.
10. Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988;319:1517-25.
11. Sica DA, Gehr TW, Duchin KL. The pharmacology and pharmacokinetics of fosinopril. Rev Contemp Pharmacother 1993;4:1-15.
12. McEvoy GK, Litvak K, Welsh OH Jr, eds. AHFS 97 drug information. Bethesda, MD: American Society of Health-System Pharmacists, 1997:1178-1322.
13. Knoll Pharmaceuticals. Mavik (trandolapril) package insert. Whippany, NJ; 1996.
14. Schwarz Pharma Pharmaceuticals. Univasc (moexipril) product monograph. Milwaukee, WI; 1996.
15. Jackson EK, Garrison JC. Renin and angiotensin. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's pharmacologic basis of therapeutics, 9th ed. New York: McGraw-Hill, 1996:733-58.
16. Riley TN, DeRuiter J. Moexipril hydrochloride (Univasc). US Pharmacist 1995;20:40-2.
17. Testa MA, Anderson RB, Nackley JF, et al. Quality of life and antihypertensive therapy in men: a comparison between captopril and enalapril. N Engl J Med 1993;328:907-13.
18. Pizzulli L, Hagendorff A, Zirbes M, et al. Influence of captopril on nitroglycerin-mediated vasodilation and the development of nitrate tolerance in the arterial and venous circulation. Am Heart J 1996;131:342-9.
19. Dakak N, Makhoul N, Flugelman MY, et al. Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990;66:608-13.
20. Van Gilst WH, De Graff PA, Scholtens E. Potentiation of isosorbide dinitrate induced coronary dilation by captopril. J Cardiovasc Pharmacol 1987;9:254-5.
21. Wantanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Preventive effects of captopril on nitrate tolerance [abstr]. Jpn Circ J 1993;57:642.
22. Katz RJ, Levy WS, Buff L Wasserman AG. Prevention of nitrate tolerance with angiotensin converting enzyme inhibitors. Circulation 1991;83:1271-7.
23. Leonetti G, Cuspidi C. Choosing the right ACE inhibitor: a guide to selection. Drugs 1995;49:516-35.
24. MacLeod EM, Bartley EA, Kripiliami KJ, Marino MR. Effect of hepatic function on disposition of fosinopril in humans. J Clin Pharmacol 1990;30:839.
25. Gill MA, Kirchain WR. Alcoholic liver disease. In: DiPiro JT, Talbert RL, Yee GC, eds. Pharmacotherapy: a pathophysiologic approach, 3rd ed. Stamford, CT: Appleton & Lange, 1997:785-800.
26. Ford NF, Lassater KC, Van Harken DR, Hammett JL, Raymond R, Manning J. Single dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment. J Clin Pharmacol 1995;35:145-50.
27. Wiseman LR, McTavish D. Trandolapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs 1994;48:72-90.
28. Grover GJ, Sleph PG, Dzwonczyk S, et al. Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection. J Pharmacol Exp Ther 1991;257:919-29.
29. Ruzicka M, Leenan FHH. Relevance of blockade of cardiac and circulatory angiotensin-converting enzyme for the prevention of volume overload-induced cardiac hypertrophy. Circulation 1995;91:16-19.
30. Ruzicka M, Skarda V, Leenan FHH. Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats. Circulation 1995;92:3568-73.
31. Leonetti G, Fogari R, Mazzola C, et al. Effects of blood pressure reduction with trandolapril and enalapril on left-ventricular hypertrophy and exercise tolerance. J Hypertens 1993;11(suppl 5):S356-7.
32. White CM, Chow MS. Angiotensin II type 1 receptor antagonists. Formulary 1996;31:1058-64.
33. Tatro DS, Olin BR, eds. Drug interaction facts. St Louis: Facts and Comparisons, 1996:27-8.
34. American Medical Association. AMA drug evaluations. Chicago: American Medical Association, 1995:601-12.
35. Simmons WD, Johnson CA. Dialysis of drugs handbook 1996. New York: McMahon Group, 1996.
36. Anonymous. Moexipril drug monograph. Micromedex 1997.
37. Schaefer RM, Schaefer L, Horl WH. Anaphylactoid reactions during hemodialysis. Clin Nephrol 1994;42(suppl 1):s44-7.
38. Schaefer RM, Fink E, Schaefer L, Barkhausen R, Kulzer P, Heidland A. Role of bradykinin in anaphylactoid reactions during hemodialysis with AN69 dialyzers. Am J Nephrol 1993;13:473-7.
39. Wakasa M, Akizawa T, Kinugasa E, Koshikawa S. Plasma bradykinin levels during hemodialysis with PAN DX and polysulphone membranes with and without ACE inhibition. Clin Nephrol 1995;44(suppl 1):S29-32.
40. Biollaz J, Waeber B, Brunner HR. Hypertensive crisis treated with orally administered captopril. Eur J Clin Pharmacol 1983;25:145-9.
41. Tschollar W, Belz GG. Sublingual captopril in hypertensive crises. Lancet 1985;2:34-5.
42. Opie LH, Jennings A. Sublingual captopril versus nifedipine in hypertensive crises [letter]. Lancet 1985;5:555.
43. Castillo AC, Rodrigues M, Gonzalez E, Rodrigues F, Estruch J. Dose-response effect of sublingual captopril in hypertensive crises. J Clin Pharmacol 1988;28:667-70.
44. Leeman M, Degaute JP. Invasive hemodynamic evaluation of sublingual captopril and nifedipine in patients with arterial hypertension after abdominal aortic surgery. Crit Care Med 1995:23:843-7.
45. Stumpf JL. Drug therapy for hypertensive crises. Clin Pharm 1988;7:582-91.
46. Strauss R, Gavras I, Vlahakos D, Gavras H. Enalaprilat in hypertensive emergencies. J Clin Pharmacol 1986;26:39-43.
47. Dipette DJ, Ferraro JC, Evans RR, Martin M. Enalaprilat, an intravenous angiotensin converting enzyme inhibitor, in hypertensive crises. Clin Pharmacol Ther 1985;38:199-204.
48. Curtiss C, Cohn JN, Vrobel T, Franciosa JA. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 1978;58:763-9.
49. Meridith PA. Trough/peak ratios for antihypertensive agents: the issues in perspective. Drugs 1994;48:661-6.
50. Frishman WH. Twenty-four-hour pressure control: approaches to assessment and efficacy of angiotensin-converting enzyme inhibitors. Adv Ther 1996;13:110-22.
51. Zannad F, Matzinger A, Larche J. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium channel antagonists. Am J Hypertens 1996;9:633-43.
52. Salvetti A, DiVenanzio L, Arrighi P, Arzilli F. Trough:peak ratio of the blood pressure response to angiotensin converting enzyme inhibitors. J Hypertens 1994;12(suppl 8):S91-5.
53. Vaur L, Dutrey-Dupagne C, Boussac J, et al. Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. J Cardiovasc Pharmacol 1995;26:127-31.
54. Rajagopalan S, Harrison DG. Reversing endothelial dysfunction with ACE inhibitors: a new TREND. Circulation 1996;94:240-3.
55. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (trial on reversing endothelial dysfunction) study. Circulation 1996;94:258-65.
56. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
57. Kober L, Torp-Peterson C, Carlsen JE, et al. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.
58. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long-Term Evaluatin (SMILE) Study Investigators. The effects of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
59. Pfefer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992;327: 669-77.
60. Fourth International Study of Infarct Survival Collaborative Group. ISIS-4. A randomized trial of intravenous magnesium sulphate, oral mononitrate and of oral captopril among 58,000 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
61. Swedburg K, Held P, Kjekshus J, et al. Effects of early administration of enalapril on mortality in patients with acute myocardial infarction: results of the cooperative north Scandinavian enalapril survival study II. N Engl J Med 1992;327:678-84.
62. Gruppo Italiano per lo Studio della Sporavvivenza nell'Infarcto Miocardio (GISSI-3). Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6 week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
63. Sleight P. Vasodilators after myocardial infarction - ISIS IV. Am J Hypertens 1994;7(suppl):102S-5.
64. Foy SG, Crozier IG, Turner JG, et al. Comparison of enalapril versus captopril on left-ventricular function and survival three months after acute myocardial infarction (the PRACTICAL study). Am J Cardiol 1994;73:1180-6.
65. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the cooperative new Scandinavian enalapril survival study II (CONSENSUS II). Am J Cardiol 1997;79:115-19.
66. Cleland JGF, Bulpitt CJ, Falk RH, et al. Is aspirin safe for patients with heart failure? Br Heart J 1995;74:215-19.
67. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992;20:1549-55.
68. Polonia J, Boaventura I, Gama G, et al. Influence of non-steroidal anti-inflammatory drugs on renal function and 24 h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens 1995;13:925-31.
69. Moore TJ, Crantz FR, Hollenberg NK, et al. Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension. Hypertension 1981;3:168-73.
70. Baur LHB, Schipperheyn JJ, VanDerLaarse A, et al. Combining salicylate and enalapril in patients with coronary artery disease and heart failure. Br Heart J 1995;73:227-36.
71. Borghi C, Bacchelli S, Ambrosioni E. The use of zofenopril and fosinopril in acute myocardial infarction and carotid artery disease. Am J Hypertens 1994;7(suppl):S96-101.
72. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987;316:1429-35.
73. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.
74. Vagelos R, Nejedly M, Wilson K, Yee G, Fowler M. Comparison of low versus high dose enalapril therapy for patients with severe congestive heart failure (CHF) [abstr]. J Am Coll Cardiol 1991;17:275A.
75. Ateshadi A, Johnson CA. Chronic renal failure. In: Young LY, Koda-Kimble MA, eds. Applied therapeutics: the clinical use of drugs, 6th ed. Vancouver, WA: Applied Therapeutics, 1995:30.1-29.
76. Thomas ER, Carter BL. Hypertension and endstage renal disease. Ann Pharmacother 1994;28:359-66.
77. Aurell M, Bjork S. Determinants of progressive renal disease in diabetes mellitus. Kidney Int 1992;41(suppl 36):S38-42.
78. Mimran A, Ribstein J. Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases. Am J Hypertens 1994;7(suppl):73S-81.
79. Keilani T, Schlueter W, Battle D. Selected aspects of ACE inhibitor therapy for patients with renal disease: impact on proteinuria, lipids and potassium. J Clin Pharmacol 1995;35:87-97.
80. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
81. Dominguez LJ, Barbagallo M, Kattah W, Garcia D, Sowers JR. Quinapril reduces microalbuminuria in essential hypertensive and in diabetic hypertensive subjects. Am J Hypertens 1995;8:808-14.
82. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577-81.
83. Trevisan R, Tiengo A, for the North-East Italy Microalbuminuria Study Group. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin dependent diabetic patients. Am J Hypertens 1995;8:876-83.
84. Maschio G, Cagnoli L, Claroni M, et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicenter, randomized, placebo-controlled study. Nephrol Dial Transplant 1994;9:265-9.